Gain Therapeutics Files 8-K
Ticker: GANX · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $50 million, $50.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Gain Therapeutics filed an 8-K, but details are scarce. Watch for more info.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on October 21, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Gain Therapeutics, Inc., but the lack of specific details requires further investigation to understand the implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific information in this particular filing creates uncertainty.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- October 21, 2024 (date) — Filing date and earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40237 (other) — SEC File Number
- 85-1726310 (other) — IRS Employer Identification No.
- 4800 Montgomery Lane , Suite 220 Bethesda , Maryland 20814 (address) — Principal executive offices
- ( 301 ) 500-1556 (phone_number) — Registrant's telephone number
FAQ
What specific event(s) are being reported in this 8-K filing by Gain Therapeutics, Inc.?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported, only that the report is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 21, 2024.
Where is Gain Therapeutics, Inc. incorporated and what is its principal executive office address?
Gain Therapeutics, Inc. is incorporated in Delaware and its principal executive offices are located at 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
What is the SEC file number and IRS Employer Identification Number for Gain Therapeutics, Inc.?
The SEC file number is 001-40237 and the IRS Employer Identification Number is 85-1726310.
Does this filing indicate any financial transactions or agreements?
The provided text of the 8-K filing does not mention any specific financial transactions, agreements, or dollar amounts. It is a general 'Other Events' filing.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 14.2 · Accepted 2024-10-21 17:22:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value GANX The NASDAQ Stock Marke
- $50 million — Value of Listed Securities ("MVLS") of $50 million required for continued listing on The N
- $50.0 million — mpany's listed securities was less than $50.0 million for the previous 30 consecutive busines
Filing Documents
- tm2426597d1_8k.htm (8-K) — 24KB
- 0001104659-24-110287.txt ( ) — 195KB
- ganx-20241021.xsd (EX-101.SCH) — 3KB
- ganx-20241021_lab.xml (EX-101.LAB) — 33KB
- ganx-20241021_pre.xml (EX-101.PRE) — 22KB
- tm2426597d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 21, 2024, Gain Therapeutics, Inc. (the "Company") received a letter from the listing qualifications department staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq") notifying the Company that the Staff had determined that the Company had regained compliance with the minimum Market Value of Listed Securities ("MVLS") of $50 million required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Requirement"), and the Company is therefore in compliance with all Nasdaq Global Market listing requirements and the matter is now closed. As previously reported in a Current Report on Form 8-K filed on July 12, 2024, the Company had received written notice from the Staff on July 11, 2024 indicating that the Company was not in compliance with the MVLS Requirement because the market value of the Company's listed securities was less than $50.0 million for the previous 30 consecutive business days. The Company had a period of 180 calendar days, or until January 7, 2025, to regain compliance with the MVLS Requirement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 21, 2024 Gain Therapeutics, Inc. By: /s/ Gene Mack Name: Gene Mack Title: Interim Chief Executive Officer and Chief Financial Officer